Finance

Beta
Lists
TRVN:OTCMKTS
Trevena Inc
$0.0010
-90.99%
(-0.010) 1D
Jun 12, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVN...
Open
$0.00
High
$0.00
Low
$0.00
Mkt. cap
959.00
Avg. vol.
127.00
Volume
145.00
52-wk high
$1.14
52-wk low
$0.00
Beta
0.63
Shares outstanding
864.00K
No. of employees
23
Open
$0.00
High
$0.00
Low
$0.00
Mkt. cap
959.00
Avg. vol.
127.00
Volume
145.00
52-wk high
$1.14
52-wk low
$0.00
Beta
0.63
Shares outstanding
864.00K
No. of employees
23
News stories
From sources across the web
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersAtlanta, Georgia, United States
SectorBiotechnology
Websitetrevena.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Revenue
-82.00K
20.00K
325.00K
283.00K
Cost of goods sold
-
-
103.00K
114.00K
Cost of revenue
-
-
103.00K
114.00K
Research and development expenses
-
-
3.13M
1.87M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
3.60M
3.88M
Operating expense
-
-
6.72M
5.75M
Total operating expenses
-
-
6.83M
5.86M
Operating income
-
-
-6.50M
-5.58M
Other non operating income
-
-
1.92M
479.00K
EBT including unusual items
-
-
-4.86M
-4.91M
EBT excluding unusual items
-
-
-4.86M
-4.91M
Income tax expense
-
-
31.00K
30.00K
Effective tax rate
-
-
-0.64%
-0.61%
Other operating expenses
-
-
-
-
Net income
-
-
-4.89M
-4.94M
Net profit margin
-
-
-1,504.92%
-1,745.23%
Earnings per share
-
-
-
-
Interest and investment income
-
-
238.00K
190.00K
Interest expense
-
-
-521.00K
-1.00K
Net interest expenses
-
-
-283.00K
189.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-6.41M
-5.48M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer